Advertisement

Keywords

Sensory Neuropathy Axonal Degeneration Sensory Loss Nerve Biopsy Chronic Inflammatory Demyelinating Polyneuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Feldman EL, Stevens MJ, Russell JW, et al (2001) Diabetic neuropathy. In: Becker KL (ed) Principles and practice of endocrinology and metabolism, 3rd edn. Lippincott, Williams & Wilkins, pp 1391–1399Google Scholar
  2. Feldman EL, Stevens MJ, Russell JW, et al (2002) Somatosensory neuropathy. In: Porte D Jr, Sherwin RS, Baron A (eds) Ellenberg and Rifkin’s diabetes mellitus, 6th edn. McGraw Hill, pp 771–788Google Scholar
  3. Simmons Z, Feldman EL (2002) Update on diabetic neuropathy. Curr Opin Neurol 15: 595–603CrossRefPubMedGoogle Scholar
  4. Windebank AJ, Feldman EL (2001) Diabetes and the nervous system. In: Aminoff MJ (ed) Neurology and general medicine, 3rd edn. Churchill Livingstone, pp 341–364Google Scholar
  5. Feldman EL, Stevens MJ, Russell JW (2002) Diabetic peripheral and autonomic neuropathy. In: Sperling MA (ed) Contemporary endocrinology: type 1 diabetes: etiology and treatment. Humana Press, pp 437–461Google Scholar
  6. Vinik AI, Erbas T, Pfeifer MA, et al (2002) Diabetic autonomic neuropathy. In: Porte Jr D, Sherwin RS, Baron A (eds) Ellenberg and Rifkin’s diabetes mellitus, 6th edition. McGraw Hill, pp 789–804Google Scholar
  7. Dyck JB, Norell JE, Dyck PJ (1999) Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 53: 2113–2121PubMedGoogle Scholar
  8. Feldman EL, Stevens MJ, Russell JW, Greene DA (2001) Diabetic neuropathy. In: Becker KL (ed) Principles and practice of endocrinology and metabolism, 3rd edition. Lippincott, Williams & Wilkins, pp 1391–1399Google Scholar
  9. Simmons Z, Feldman EL (2002) Update on diabetic neuropathy. Curr Opin Neurol 15: 595–603CrossRefPubMedGoogle Scholar
  10. Windebank AJ, Feldman EL (2001) Diabetes and the nervous system. In: Aminoff MJ (ed) Neurology and general medicine, 3rd edition. Churchill Livingstone, pp 341–364Google Scholar
  11. Burns DJ, Bate D (1998) Neurology and the kidney. J Neurol Neurosurg Psychiatry 65: 810–821Google Scholar
  12. Davies L (1994) Vasculitic neuropathy. Baillieres Clin Neurol 1: 193–210Google Scholar
  13. Griffin JW (2001) Vasculitic neuropathies. Rheum Dis Clin North Am 4: 751–760Google Scholar
  14. Olney RK (1998) Neuropathies associated with connective tissue disease. Semin Neurol 18: 63–72PubMedGoogle Scholar
  15. Rosenbaum R (2001) Neuromuscular complications of connective tissue diseases. Muscle Nerve 2: 154–169Google Scholar
  16. Said G (1999) Vasculitic neuropathy. Curr Opin Neurol 5: 627–629Google Scholar
  17. Collins MP, Periquet MI, Mendell JR, et al (2003) Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 61: 623–630PubMedGoogle Scholar
  18. Benito-Leon B, et al (1998) Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responding to intravenous immunoglobulin and radiotherapy. J Neurol Sci 158: 113–117PubMedGoogle Scholar
  19. Davies LE, Drachman DB (1972) Myeloma neuropathy: successful treatment of two patients and review of cases. Arch Neurol 27: 507–511Google Scholar
  20. Eurelings M, Moons KGM, Notermans NC, et al (2001) Neuropathy and IgM M-proteins. Neurology 56: 228–233PubMedGoogle Scholar
  21. Miralles GD, O’Fallon JR, Talley NJ (1992) Plasma cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Eng J Med 327: 1919–1923Google Scholar
  22. Notermans NC, Franssen H, Eurelings M, et al (2000) Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 23: 73–79CrossRefPubMedGoogle Scholar
  23. Ropper AH, Gorson KC (1998) Neuropathies associated with with paraproteinemia. N Eng J Med 338: 1601–1607Google Scholar
  24. Simmons Z, Albers JW, Bromberg MB, et al (1995) Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 118 (Pt 2): 359–368PubMedGoogle Scholar
  25. Simmons Z (1999) Paraproteinemia and neuropathy. Curr Opinion Neurol 12: 589–595Google Scholar
  26. Simmons Z, Albers JW, Bromberg MB, et al (1993) Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 43: 2202–2209PubMedGoogle Scholar
  27. Adams D (2001) Hereditary and acquired amyloid neuropathies. J Neurol 248: 647–57CrossRefPubMedGoogle Scholar
  28. Comenzo RL (2000) Primary systemic amyloidosis. Curr Treat Options Oncol 1: 83–89PubMedGoogle Scholar
  29. Kyle RA, Gertz MA, Greipp PR, et al (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan, prednisone, and colchicine. N Eng J Med 336: 1202–1207Google Scholar
  30. Reilly MM, Staunton H (1996) Peripheral nerve amyloidosis. Brain Pathol 2: 163–177Google Scholar
  31. Quattrini A, Nemni R, Sferrazza B, et al (1998) Amyloid neuropathy simulating lower motor neurone disease. Neurology 51: 600–602PubMedGoogle Scholar
  32. Grisold W, Piza-Katzer H, Herczeg E (2000) Intraneural nerve metastasis with multiple mononeuropathies. J Periph Nerv Sys 5: 163–167Google Scholar
  33. Krarup C, Crone C (2002) Neurophysiological studies in malignant disease with particular reference to involvement of peripheral nerves. J Neurol 249: 651–661CrossRefPubMedGoogle Scholar
  34. Odabasi Z, Parrot JH, Reddy VVB, et al (2001) Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: a case report and review of literature. J Periph Nerv Sys 6: 197–203Google Scholar
  35. Camdessanche JP, Antoine JC, Honnorat J, et al (2002) Paraneoplastic peripheral neuropathy associated with anti Hu antibodies. Brain 125: 166–175CrossRefPubMedGoogle Scholar
  36. Chinn JS, Schuffler MD (1988) Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 95: 1279–1286PubMedGoogle Scholar
  37. Grisold W, Drlicek M (1999) Paraneoplastic neuropathy. Curr Opin Neurol 12: 617–625CrossRefPubMedGoogle Scholar
  38. Krarup C, Crone C (2002) Neurophysiological studies in malignant disease with particular reference to involvement of peripheral nerves. J Neurol 249: 651–661CrossRefPubMedGoogle Scholar
  39. Storstein A, Vedeler C (2001) Neuropathy and malignancy: a retrospective survey. J Neurol 248: 322–327CrossRefPubMedGoogle Scholar
  40. Dalmau J, Schold SC Jr (2000) Paraneoplastic diseases of the nervous system. In: Evans RW, Baskin DS, Yatsu FM (eds) Prognosis of neurological disorders. Oxford University Press, New York Oxford, pp 458–469Google Scholar
  41. Rosenfeld MR, Dalmau J (1999) Paraneoplastic syndromes and motor dysfunction. In: Younger DS (ed) Motor disorders. Lippincott, Philadelphia, pp 397–405Google Scholar
  42. Vigliani MC, Polo P, Chio P, et al (2000) Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. J Neurol 247: 778–782CrossRefPubMedGoogle Scholar
  43. Cherry CL, McArthur JC, Hoy JF, et al (2003) Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 26: 195–207CrossRefPubMedGoogle Scholar
  44. Kolson DL, Gonzalez-Scarano F (2001) HIV-associated neuropathies: role of HIV-1, CMV, and other viruses. J Peripher Nerv Syst 6: 2–7CrossRefPubMedGoogle Scholar
  45. Luciano CA, Pardo CA, McArthur JC (2003) Recent developments in the HIV neuropathies. Curr Opin Neurol 16: 403–409CrossRefPubMedGoogle Scholar
  46. Simpson DM (2002) Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 8[Suppl 2]: 33–41PubMedGoogle Scholar
  47. Verma A (2001) Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 6: 8–13CrossRefPubMedGoogle Scholar
  48. Collins SL, Moore RA, McQuay HJ, et al (2000) Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20: 449–458CrossRefPubMedGoogle Scholar
  49. Fox RJ, Galetta SL, Mahalingam R, et al (2001) Acute, chronic, and recurrent varicella zoster virus neuropathy without zoster rash. NeurologyGoogle Scholar
  50. Greenstein P (2002) Tick paralysis. Med Clin North Am 86(2): 441–446CrossRefPubMedGoogle Scholar
  51. Halperin JJ (2003) Lyme disease and the peripheral nervous system. Muscle Nerve 28: 133–143PubMedGoogle Scholar
  52. Nations SP, Katz JS, Lyde CB, et al (1998) Leprous neuropathy: an American perspective. Semin Neurol 18(1): 113–124PubMedGoogle Scholar
  53. Rambukkana A (2000) How does Mycobacterium leprae target the peripheral nervous system? Trends Microbiol 8(1): 23–28CrossRefPubMedGoogle Scholar
  54. Roman G (1998) Tropical myeloneuropathies revisited. Curr Opin Neurol 11: 539–544PubMedGoogle Scholar
  55. Sica RE, Gonzalez Cappa SM, et al (1995) Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Bull Soc Pathol Exot 88: 156–163PubMedGoogle Scholar
  56. Hiraga A, Mori M, Ogawara K, et al (2003) Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology 61: 471–474PubMedGoogle Scholar
  57. Kuwabara S, Ogawara K, Mizobuchi K, et al (2001) Mechanisms of early and late recovery in acute motor axonal neuropathy. Muscle Nerve 24: 288–291PubMedGoogle Scholar
  58. Tekgul H, Serdaroglu G, Tutuncuoglu S (2003) Outcome of axonal and demyelinating forms of Guillain-Barre syndrome in children. Pediatr Neurol 28: 295–299CrossRefPubMedGoogle Scholar
  59. Donofrio P (2003) Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 28: 273–292CrossRefPubMedGoogle Scholar
  60. Lindenbaum Y, Kissel JT, Mendell JR (2001) Treatment approaches for Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Clin 19: 187–204CrossRefPubMedGoogle Scholar
  61. Dalakas MC (2002) Mechanisms of action of IVIG and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59[Suppl 6]: S13–21PubMedGoogle Scholar
  62. Ensrud ER, Krivickas LS (2001) Acquired inflammatory demyelinating neuropathies. Phys Med Rehabil Clin N Am 12: 321–334PubMedGoogle Scholar
  63. Hartung HP, Willison HJ, Kieseier BC (2002) Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. Curr Opin Neurol 15(5): 571–577CrossRefPubMedGoogle Scholar
  64. Hughes AC, Wijdicks EFM, Bahron R, et al (2003) Practice parameter: immunotherapy for Guillain-Barre syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61: 736–740PubMedGoogle Scholar
  65. Kieseier BC, Hartung HP (2003) Therapeutic strategies in the Guillain-Barre syndrome. Semin Neurol 23: 159–168PubMedGoogle Scholar
  66. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathies (CIDP): report from the Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41: 617–618Google Scholar
  67. Hahn AF, Bolton CF, Zochodne D, et al (1996) Intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. A double blind placebo controlled, cross over study. Brain 119: 1067–1077PubMedGoogle Scholar
  68. Cocito D, Durelli L, Isoardo G (2003) Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinemia. Acta Neurol Scand 108: 274–280CrossRefPubMedGoogle Scholar
  69. Eurelings M, Moons KG, Notermans NC, et al (2001) Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 56: 228–233PubMedGoogle Scholar
  70. Gorson KC, Ropper AH, Weinberg DH, et al (2001) Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 24: 778–786CrossRefPubMedGoogle Scholar
  71. Donofrio P (2003) Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 28: 273–292CrossRefPubMedGoogle Scholar
  72. Van Doorn PA, Garssen MP (2002) Treatment of immune neuropathies. Curr Opin Neurol 15: 623–631PubMedGoogle Scholar
  73. Willison HJ, O’Hanlon GM (1999) The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 100: 3–12CrossRefPubMedGoogle Scholar
  74. Metz J (1992) Cobalamin deficiency and the pathogenesis of nervous system disease. Annu Rev Nutr 12: 59–79CrossRefPubMedGoogle Scholar
  75. Saperstein DS, Barohn RJ (2002) Peripheral neuropathy due to cobalamin deficiency. Curr Treat Options Neurol 4: 197–201PubMedGoogle Scholar
  76. Saperstein DS, Wolfe GI, Gronseth GS, et al (2003) Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 60: 1296–1301CrossRefPubMedGoogle Scholar
  77. Tefferi A, Pruthi RK (1994) The biochemical basis of cobalamin deficiency. Mayo Clin Proc 2: 181–186Google Scholar
  78. Maryniak O (1984) Severe peripheral neuropathy following gastric bypass surgery for morbid obesity. Can Med Assoc J 131(2): 119–120PubMedGoogle Scholar
  79. Bernstein AL (1990) Vitamin B6 in clinical neurology. Ann NY Acad Sci 585: 250–260PubMedGoogle Scholar
  80. Snodgrass SR (1992) Vitamin neurotoxicity. Mol Neurobiol 6: 41–73PubMedGoogle Scholar
  81. Cockerell OC, Ormerod IE (1993) Strachan’s syndrome: variation on a theme. J Neurol 240: 315–318CrossRefPubMedGoogle Scholar
  82. Kril JJ (1996) Neuropathology of thiamine deficiency disorders. Metab Brain Dis 11:9–17CrossRefPubMedGoogle Scholar
  83. Traber MG, Sokol RJ, Ringel SP, et al (1987) Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med 317: 262–265PubMedGoogle Scholar
  84. Mizisin AP, Powell HC (1995) Toxic neuropathies. Curr Opin Neurol 8: 367–371PubMedGoogle Scholar
  85. O’Donoghue JL, Nasr AN, Raleigh RL (1977) Toxic neuropathy — an overview. J Occup Med 19: 379–382PubMedGoogle Scholar
  86. Chu CC, Huang CC, Chu NS, et al (1996) Carbon disulfide induced polyneuropathy: sural nerve pathology, electrophysiology, and clinical correlation. Acta Neurol Scand 94: 258–263PubMedGoogle Scholar
  87. Hageman G, van der Hoek J, van Hout M, et al (1999) Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol 246: 198–206CrossRefPubMedGoogle Scholar
  88. Vasilescu C, Florescu A (1980) Clinical and electrophysiological studies of carbon disulphide polyneuropathy. J Neurol 224: 59–70CrossRefPubMedGoogle Scholar
  89. Jamal GA (1997) Neurological syndromes of organophosphorus compounds. Adverse Drug React Toxicol Rev 16: 133–170PubMedGoogle Scholar
  90. Jokanovic M, Stukalov PV, Kosanovic M (2002) Organophosphate induced delayed polyneuropathy. Curr Drug Target CNS Neurol Disord 1: 593–602Google Scholar
  91. Marrs TC (1993) Organophosphate poisoning. Pharmacol Ther 58: 51–66CrossRefPubMedGoogle Scholar
  92. Koike H, Mori K, Misu K, et al (2001) Painful alcoholic polyneuropathy with predominant small fiber loss and normal thiamine status. Neurology 56: 1727–1732PubMedGoogle Scholar
  93. Koike H, Iijima M, Sugiura M, et al (2003) Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 54: 19–29CrossRefPubMedGoogle Scholar
  94. Monforte R (1995) Autonomic and peripheral neuropathies in patients with chronic alcoholism. Arch Neurol 52: 45–51PubMedGoogle Scholar
  95. Wöhrle JC, Spengos K, Steinke W, et al (1998) Alcohol related acute axonal polyneuropathy. Arch Neurol 55: 1329–1334PubMedGoogle Scholar
  96. Fernando Roth R, Itabashi H, Louie J, et al (1990) Amiodarone toxicity: myopathy and neuropathy. Am Heart J 119: 1223–1225PubMedGoogle Scholar
  97. Hilleman D, Miller MA, Parker R, et al (1998) Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 18 (6 Pt 2): 138–145Google Scholar
  98. Shinohara Y, Yamaguchi F, Gotoh F (1977) Toxic neuropathy as a complication of thiophenicol therapy. Eur Neurol 16: 161–164PubMedGoogle Scholar
  99. Altiparmak MR, Pamuk ON, Pamuk GE, et al (2002) Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol 20[Suppl] 26: S13–S16PubMedGoogle Scholar
  100. Kuncl RW, Cornblath DR, Avila O, et al (1989) Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve 12: 360–364CrossRefPubMedGoogle Scholar
  101. Kuncl RW, Duncan G, Watson D, et al (1987) Colchicine myopathy and neuropathy. N Engl J Med 316: 1562–1568PubMedGoogle Scholar
  102. Gutmann L, Martin JD, Welton W (1976) Dapsone motor neuropathy: an axonal disease. Neurology 26: 514–516PubMedGoogle Scholar
  103. Waldinger TP, Siegle RJ, Weber W, et al (1984) Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol 120: 356–359PubMedGoogle Scholar
  104. Frisoni GB, Di Monda V (1989) Disulfiram neuropathy: a review (1971–1988) and report of a case. Alcohol Alcohol 24: 429–437PubMedGoogle Scholar
  105. Mokri B, Ohnishi A, Dyck PJ (1981) Disulfiram neuropathy. Neurology 31: 730–735PubMedGoogle Scholar
  106. Adelsberger H, Lersch C, Quasthoff S, et al (2004) Oxalinplatin-induced neuropathy differs from cisplatin and taxol neuropathy due to acute alteration of voltage-gated sodium channels in sensory neurons. Clin Neurophysiol 111: 143Google Scholar
  107. Casey EB, Jellife EM, Le Quesne PM, et al (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96: 69–86PubMedGoogle Scholar
  108. Delattre JY, Vega F, Chen Q (1995) Neurologic complications of immunotherapy. In: Wiley RG (ed) Neurological complications of cancer. Dekker, New York, pp 267–293Google Scholar
  109. Fazeny B, Zifko U, Meryn S, et al (1996) Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel-a phase II study. Cancer Chemother Pharmacol 39: 150–156CrossRefPubMedGoogle Scholar
  110. Forman A (1990) Peripheral neuropathy in cancer patients: clinical types, etiology, and presentation, part 2. Oncology Williston Park 4: 85–89PubMedGoogle Scholar
  111. Harmers FP, Gispen WH, Neijt JP (1991) Neurotoxic side-effects of cisplatin. Eur J Cancer 27: 372–376PubMedGoogle Scholar
  112. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9–17CrossRefPubMedGoogle Scholar
  113. Sahenk Z, Barohn R, New P, et al (1994) Taxol neuropathy; electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51: 726–729PubMedGoogle Scholar
  114. Verstappen CC, Heimans JJ, Hoekman K, et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549–1563CrossRefPubMedGoogle Scholar
  115. Walsh RJ, Clark AW, Parhad IM (1982) Neurotoxic effects of cisplatin therapy. Arch Neurol 39: 719–720PubMedGoogle Scholar
  116. Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opinion Neurol 12: 565–571Google Scholar
  117. Bansal SK, Haldar N, Dhand UK, et al (1991) Phrenic neuropathy in arsenic poisoning. Chest 100: 878–880PubMedGoogle Scholar
  118. Donofrio PD, Wilbourn AJ, Albers JW, et al (1987) Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve 10: 114–120CrossRefPubMedGoogle Scholar
  119. Oh SJ (1991) Electrophysiological profile in arsenic neuropathy. J Neurol Neurosurg Psychiatry 54: 1103–1105PubMedGoogle Scholar
  120. Albers JW, Kallenbach LR, Fine LJ, et al (1988) Neurologic abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol 24: 651–659CrossRefPubMedGoogle Scholar
  121. Chu CC, Huang CC, Ryu SJ, et al (1998) Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand 98: 461–465PubMedGoogle Scholar
  122. Windebank AJ (1993) Metal neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) Peripheral neuropathy, 3rd edn. Saunders, p 1549Google Scholar
  123. Windebank AJ (1993) Metal neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) Peripheral neuropathy, 3rd edn. Saunders, p 1549–1570Google Scholar
  124. Kuhlenbaumer G, Young P, Hunermund G, et al (2002) Clinical features and molecular genetics of hereditary peripheral neuropathies. J Neurol 249(12): 1629–1650PubMedGoogle Scholar
  125. Reilly MM (2000) Classification of the hereditary motor and sensory neuropathies. Curr Opin Neurol 13(5): 561–564PubMedGoogle Scholar
  126. Roa BB, Garcia CA, Lupski JR (1991-1992) Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy. Int J Neurol 25–26: 97–107PubMedGoogle Scholar
  127. Trobaugh-Lotrario AD, Smith AA, Odom LF (2003) Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol 40(1): 39–43CrossRefPubMedGoogle Scholar
  128. Gemignani F, Marbini A (2001) Charcot-Marie-Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2. J Neurol Sci 184(1): 1–9CrossRefPubMedGoogle Scholar
  129. Pareyson D, Sghirlanzoni A, Bolti S, et al (1999) Charcot-Marie-Tooth disease type 2 and P0 gene mutations. Neurology 52(5): 1110–1111PubMedGoogle Scholar
  130. Vance JM (1999) Charcot-Marie-Tooth disease type 2. Ann NY Acad Sci 883: 42–46PubMedGoogle Scholar
  131. Andersson PB, Yuen E, Parko K, et al (2000) Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 54: 40–44PubMedGoogle Scholar
  132. Chance PF (1999) Overview of hereditary neuropathy with liability to pressure palsies. Ann NY Acad Sci 883: 14–21PubMedGoogle Scholar
  133. De Jonghe P, Timmerman V, Nelis E, et al (1997) Charcot-Marie-Tooth disease and related peripheral neuropathies. J Peripher Nerv Syst 2: 370–387PubMedGoogle Scholar
  134. Pareyson D, Taroni F (1996) Deletion of the PMP22 gene and hereditary neuropathy with liability to pressure palsies. Curr Opin Neurol 9: 348–354PubMedGoogle Scholar
  135. Kochar DK, Poonia A, Kumawat BL, et al (2000) Study of motor and sensory nerve conduction velocities, late responses (F-wave and H-reflex) and somatosensory evoked potential in latent phase of intermittent acute porphyria. Electromyogr Clin Neurophysiol 40(2): 73–79PubMedGoogle Scholar
  136. Meyer UA, Schuurmans MM, Lindberg RL (1998) Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 18(1): 43–52PubMedGoogle Scholar
  137. Muley SA, Midani HA, Rank JM, et al (1998) Neuropathy in erythropoietic protoporphyrias. Neurology 51(1): 262–265PubMedGoogle Scholar
  138. Wikberg A, Andersson C, Lithner F (2000) Signs of neuropathy in the lower legs and feet of patients with acute intermittent porphyria. J Intern Med 248(1): 27–32CrossRefPubMedGoogle Scholar
  139. Kuhlenbaumer G, Young P, Hunermund G, et al (2002) Clinical features and molecular genetics of hereditary peripheral neuropathies. J Neurol 249(12): 1629–1650PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2005

Personalised recommendations